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Polycyclic and halogenated aromatic hydrocarbons (PAHs and HAHs) 
are widespread and persistent environmental contaminants. Most of their 
toxicological effects are mediated through activation of the aryl hydrocarbon 
receptor (AhR), which leads to transcriptional activation of cytochrome P-450 
lA l and 1A2 (CYP lA l/2) genes. Induction of CYP lA l/2 increases drug 
metabolism and enhances the generation of reactive oxygen species (ROS) in 
vivo. Oxidative stress is an important mediator of various neurological and 
hepatic disorders. In the brain, oxidative damage can alter key components 
of glutamate homeostasis, such as glutamine synthetase (GS). This change 
can generate abnormally elevated extracellular glutamate, and lead to 
excitotoxicity.
PAHs and HAHs have been shown to induce CYP lA l in rat brain. 
However, whether the induction of CYP lA l can cause oxidative damage or 
interact with other pathologies in the central nervous system has not been 
reported.
In the present study, we investigated the effect of CYP lA l induction 
on oxidative status in the brain and liver. We demonstrated that induction of 
CYP lA l by 3-methylcholanthrene (3-MC) did not oxidize proteins or lipids, 
or decrease GS activity in rat brain and liver. Furthermore, the induction of 
CYP lA l in the brain and liver did not enhance the extent of lipid 
peroxidation in either tissue following oxidative challenge. If increased CYP 
lA l activity in the brain and liver following 3-MC treatment leads to 
increased ROS formation, the increase is insufficient to overwhelm the 
endogenous antioxidant defense system, produce detectable oxidative 
damage, and alter glutamate homeostasis.
u
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Abbreviations
AhR: aryl hydrocarbon receptor
AhREs: aryl hydrocarbon-response elements
Arnt: aryl hydrocarbon receptor nuclear translocator
CNS: central nervous system
CYP: cytochrome P-450
CYP lA l:  cytochrome P-450 lA l
CYP 1A2: cytochrome P-450 1A2
CYP 2E1: cytochrome P-450 2E1
EROD: ethoxyresorufin O-deethylase
GS: glutamine synthetase
GSH: glutathione
GST : glutathione S-transferase
HAHs: halogenated aromatic hydrocarbons
H2O 2 : hydrogen peroxide
Hsp90: heat shock protein 90
3-MC: 3-methylchoianthrene
a-NF: a-naphthoflavone, CYP lA l inhibitor
P-NF: P-naphthoflavone, CYP lA l inducer
O2 : superoxide anion
O H : hydroxyl radical
PAHs: polycyclic aromatic hydrocarbons
ROS: reactive oxygen species
TEARS: thiobarbitunc acid-reactive substance
TCDD: 2, 3, 7, 8-tetrachloro dibenzo-p-dioxin
UDP-GT : UDP glucuronosyltransferase
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Introduction:
Polycyclic and Halogenated Aromatic Hydrocarbons:
Polycyclic aromatic hydrocarbons (PAHs) and halogenated aromatic 
hydrocarbons (HAHs) are widely distributed environmental toxins. Major 
sources of PAH exposure include cigarette smoke, smoked food products, 
and air pollution (Costa, 1998). The HAH family includes polychlorinated 
dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and 
polychlorinated biphenyls (PCBs). HAHs are mainly industrial contaminants. 
PCBs are used in heat transfer fluid. PCDDs and PCDFs are byproducts in 
the synthesis of PCB, phenoxyherbicides, and chlorinated phenols. PCDDs 
are also produced by paper mills, forest fires, and automobile exhaust (Costa, 
1998).
In spite of wide exposure, the levels of PAHs in body tissues are 
normally unmeasurable (Wolff, et.al., 1996). PAHs are typically short lived 
in the body and are metabolized by several cytochrome P-450s (CYPs) to 
electrophilic derivatives. The principle enzymes involved in PAH metabolism 
are the lA l and 1A2 subtypes of cytochrome P-450 (CYP lA l/2). 
Cytochrome P-450 2B1 (CYP 2B1) also plays a role in PAH metabolism 
(Hankinson, 1995). In contrast, HAHs are relatively resistant to metabolism
1
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and more likely to build up in liver and adipose tissue upon exposure 
(Hankinson, 1995; Abraham, et.al., 1988). The apparent half life for 2, 3, 7, 
8-tetrachloro dibenzo-p-dioxin (TCDD) is up to several weeks in rodents 
(Rose, et.al., 1976), and is even longer in primates (Krowke, 1986; Poiger 
and Schlater, 1986).
Most of the toxic effects for PAHs and HAHs are caused by activation 
of the aryl hydrocarbon receptor (AhR) (Hankinson, 1995; Dogra, et.al., 
1998). Both PAHs and HAHs can transcriptionally induce biotransforming 
phase I and conjugating phase II metabolic enzymes (Hankinson, 1995; 
Poellinger, 1995). The induction of these enzymes significantly changes the 
metabolism for exogenous drugs and toxicants (Pitot HI, 1995; Parkinson, 
1995). The attack of the electrophilic metabolites of PAHs on DNA leads to 
mutation and tumor formation. Long term exposure of PAHs and HAHs have 
been reported to cause sarcoma, hepatic cancer, and breast cancer in rodents 
(Pitot ni, 1995; Kociba, 1982). In addition, toxicities for PAHs and HAHs 
also include reproductive problems (Tomas, 1995; Brouwer, et.al., 1995), 
endocrine dysfunction (Capen, 1995), developmental retardation (Brouwer, 
et.al., 1995), and cardiovascular pathology (Ramos, et.al., 1995). A 
considerable body of research in the last fifteen years has established specific
2
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
biological cascades involved in the effects of PAHs and HAHs. PAHs and 
HAHs alter intracellular Ca^  ̂homeostasis (Costa, 1998), transcriptionally 
induce specific genes through the Aryl hydrocarbon receptor (AhR) (Nobert 
and Gonzalez, 1987; Quattrochi, 1989; Landers, 1991), and induce other 
genes not associated with AhR (Okey, et.al., 1994).
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Figure 1. Basic scheme for the transcriptional activation o f CYP lA l/2  genes by PAHs 
and HAHs. TCDD, tetrachloro dibenzo-p-dioxin; MC, 3- methylcholanthrene; AhR, aryl 
hydrocarbon receptor; Arnt, AhR nuclear translocator protein; AhREs, aryl hydrocarbon 
receptor-responsive element; lA l, CYP lA l;  1A2, CYP 1A2. (Okey, et.al, 1994)
PAHs and HAHs bind to a cytosolic protein, AhR, when they enter into 
the cells. Latent AhR is complexed with heat shock protein 90 (Hsp90). 
Following binding, AhR is activated and the complex is transported into the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Following binding, AhR is activated and the complex is transported into the 
nucleus. Hsp90 is then released from the complex and the transformed 
complex dimerizes with the aryl hydrocarbon nuclear translocator (Amt).
The AhR-Amt heterodimer binds to specific DNA sequences, known as the 
aryl hydrocarbon-response elements (AhREs), and induces the transcription 
of numerous metabolic enzymes, cytokines and growth factors (Okey, et.al.,
1994). The AhRE sequence, located upstream from the activated gene, 
functions as an enhancer region (Dogra, et.al., 1998). Genes encoding both 
phase I and phase II enzymes can be transcriptionally induced by PAHs 
through this AhR-dependent mechanism. These genes include the phase I 
enzymes CYP 1 Al/2 and aldehyde dehydrogenase (ALDH), and the phase II 
enzyme glutathione S-transferase (GST) (Okey, et.al., 1994).
TCDD, 3-Methylcholanthrene (3-MC), and p-naphthoflavone (P-NF) 
are potent CYP 1A1 inducers. These compounds can induce CYP 1A1 in the 
liver and also extrahepatic tissues (Juchau, et.al., 1979; Schilter and 
Omiecinski, 1994; Unkila, et.al., 1993). For example, 3-MC (5 injections of 
110 pmol/Kg) induces CYP 1A1 in both neurons and glial cells one day after 
treatment (Dhawan, A., 1990).
4
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Cytochrome P-450:
Cytochrome P-450 (CYP) is a group of NADPH-dependent, oxidative 
enzymes capable of metabolizing a number of xenobiotics and endogenous 
compounds (Gonzalez, 1991). All CYPs are hemoproteins with a cysteine- 
thiolate ligand binding to heme iron (Gonzalez, 1991). CYPs can be 
classified in two general classes based on their means for obtaining electrons 
from NADPH and, in addition, their intracellular location in eukaryotes 
(Gonzalez, 1991). Mitochondrial CYPs, such as CYP llA  (side-chain 
cleavage cytochrome P-450) and CYP 17, are found exclusively in the inner 
mitochondrial membrane and are involved in steroid biosynthesis. They 
receive electrons via an iron-sulfur protein from flavin adenine dinucleotide 
(FAD)-containing enzyme (Gonzalez, 1991). The second class of CYPs is 
bound to microsomal membranes, and mainly involved in metabolism of 
foreign compounds. These microsomal CYPs obtain electrons via NADPH- 
cytochrome P-450 reductase, and cytochrome bs (Gonzalez, 1991). The 
microsomal CYPs are divided into the four gene families: CYP 1, 2, 3, and 4. 
All CYPs within a single gene family exhibit greater than 40% sequence 
homology, and CYPs within the same subfamily have more than 55% identity 
in sequences (Gonzalez, 1991). CYPs catalyze one-electron delivery
5
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oxidative reactions in vivo and in vitro, such as carbon hydroxylation, 
heteroatom release reactions, and oxidation of unsaturated bonds 
(Guengerich, 1991).
Multiple cytochrome P450 isozymes have been purified and 
characterized in different tissues in rodents and mammals. The earliest work 
was conducted on hepatic enzymes, due to the relatively high concentration 
of CYP and the significance of the liver in metabolism of various drugs and 
cholesterol. The expression, function, and regulation of isoforms of CYP 
differ among species. Human liver microsomes contain relatively high levels 
of CYP 1A2, but not CYP 1A1. In contrast to CYP 1 A l, CYP 1A2 is not 
expressed in extrahepatic tissues (Parkinson, 1995). The most abundant 
CYP in mammalian and rodent liver is the CYP 3A gene family. CYPs 2A, 
2C, 2D, 2E1, and 4A are also constitutively expressed in their liver 
(Gonzalez, 1991; Funae and Imaoka, 1991). The hepatic CYPs biotransform 
a wide range of xenobiotics and endogenous compounds (Parkinson, 1995). 
The expression and activity of different isoforms of CYP in the liver are 
regulated by numerous compounds (Parkinson, 1995; Dogra, et.al., 1998). 
For example, ethanol is a potent CYP 2E1 inducer, while PAHs and HAHs
6
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markedly induce CYP lA l in the liver. Inhibition or induction of CYPs 
affects the rate of xenobiotic transformation (Parkinson, 1995).
CYP enzymes have been detected in the brain. In untreated rats, the 
brain microsomal CYP concentration is approximately 1 %-3% of that found 
in the liver (Warner, et.al., 1988). The amount of CYP is unevenly 
distributed among brain regions. Major isoforms of hepatic CYP, such as 
CYP 3A2, 2C11, and 2A1, are either undetectable or only account for a small 
fraction of brain CYP (Warner, et.al., 1991). CYP lA l/2, 2B1, 3A1, and 
2E1 are the main subtypes of CYP detected in the brain by 
immunohistochemical studies, western blotting, and RT-PCR (Warner, et.al., 
1991; Schilter and Omiecinski, 1994). CYP lA l/2  have been detected in 
both neurons and glial cells (Kohler, et.al., 1988). CYP lA l/2 mRNA and 
enzyme are present in the striatum, hypothalamus, olfactory bulbs, and, to a 
lesser extent, in other regions of the brain (Kohler, et.al., 1988; Scholter and 
Omiecinski, 1994). In contrast to the liver, exposure to the well-known 
hepatic CYP inducers, including PAHs, ethanol, and barbiturates, produces 
no more than a 150% increases in CYP activity in the rat brain, while liver 
CYP activity increases by an order of magnitude (Rouet, et.al, 1981; 
Srivastava, et.al, 1983).
7
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In spite of relatively low concentrations in the brain, CYPs have very 
important physiological functions and toxicological consequences in the 
central nervous system (CNS). Brain CYPs metabolize drugs entering into 
brain, regulate intracellular cholesterol levels, activate signal transduction via 
the formation of arachidonic acid, and regulate vascular tone (Warner, et.al., 
1991). In addition, CYPs produce cytotoxic metabolites from industrial 
solvents and aromatic hydrocarbons in the brain. For example, bis 
(chloromethyl) ether, and acrylonitrile can cause glioma via a CYP 2E1 
metabolite in experimental animals (Hopwell and Wright, et.al., 1969; 
Maltony, et.al., 1982). After ethanol treatment, increased generation of 
oxygen radicals in rat brain and astrocyte cultures can be partially inhibited 
by an antibody against CYP 2E1 (Bondy and Guo, 1994; Montoliu, 1995).
The CYP catalytic cycle involves the binding of the enzymes to 
substrate, followed by binding of molecular oxygen to the heme in CYP, 
activation of the complex to a reactive intermediate, and release of 
hydroxylated substrate (Park, et.al., 1996). Autooxidation of the cytochrome 
P-450 complex produces superoxide (Kappus, 1991). The dismutation of 
superoxide anion leads to the formation of hydrogen peroxide. OH , the most
8
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reactive oxygen radical, is produced by Fenton’s reaction when hydrogen 
peroxide reacts with reduced metalloproteins (Kappus, 1991).
Induction of CYPs by various substances enhances ROS generation in 
vivo and in vitro. The well known example is ethanol-induced oxidative 
stress in liver. After ethanol administration, an increase in ROS level and 
increase in lipid peroxidation occur. These effects can be effectively 
inhibited by antibody against CYP 2E1 (Higuchi, et.al., 1996; Lieber, 1997). 
Induction of CYP 1 Al by TCDD has been reported to cause oxidative DNA 
damage in hepatoma cells. The increased generation of 8-oxo-2’- 
deoxyguanosine, a biomarker of oxidative DNA damage, can be reduced by a 
CYP lA l inhibitor (Park, et.al., 1996).
Reactive Oxygen Species and Oxidative Stress;
Various kinds of neurological disorders and hepatic injuries involve 
oxidative stress. These include stroke, Alzheimer’s disease, Amyotrophic 
Lateral Sclerosis, Parkinson Disease, liver fibrogenesis, and alcoholic liver 
(Wilson, 1997; Markesbery, 1997; Jenner and Olanow, 1996; Liu, 1996; 
Lieber, 1997). In addition, oxidative stress plays a role in various age- 
associated diseases, including atherosclerosis, neoplastic diseases, diabetes, 
and chronic inflammatory diseases (Stohs, 1995).
9
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Reactive oxygen species (ROS) are generated as intermediates during 
the reduction of oxygen to water. ROS include superoxide anion (O2 ' ), 
hydrogen peroxide (H2O2), hydroxyl radical (OH ), singlet oxygen ( 0̂ 2 ) and 
peroxynitrite (ONOO ■) (Junod, 1986; Powis, 1989). Unpaired electrons in 
the outer shell make ROS very unstable. They can react with other molecules 
to gain or lose electrons (Downey, 1990). ROS are capable of oxidizing 
proteins, lipids, and nucleic acids. Oxidation of proteins leads to changes in 
enzyme activity, and often leads to more rapid degradation of the respective 
protein (Stadtman, 1992). Lipid peroxidation damages cell membrane as well 
as extracellular lipids, and disrupts cellular homeostasis (Kappus, 1991). 
Oxidation of nucleic acids leads to strand breaks and hydroxylated 
nucleosides. Misrepair of the DNA lesion results in mutagenicity and even 
carcinogenesis (Halliwell, et.al., 1991). Therefore, the consequences of ROS 
exposure include altered gene regulation and signal transduction, apoptosis, 
necrosis, fibrosis, and carcinogenesis (Kaplowitz and Tsukamoto, 1996).
10
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Figure 2. Schematic outline for the source o f oxidative stress and consequences o f  ROS 
exposure. P450 (2E1), CYP 2E1; O2 , superoxide anion; OH, hydroxyl radical; H 2O2 , 
hydrogen peroxide; GSHm, mitochondrial GSH; TNF, tumor necrosis factor; LPO, lipid 
peroxidation. (Kaplowitz and Tsukamoto, 1996)
In most circumstances, ROS can be effectively scavenged by 
endogenous enzymatic and non-enzymatic anti oxidants (Machlin and 
Bendich., 1987; Sies, 1997). However, in pathological situations, the 
generation of ROS overwhelms the antioxidant defense (Sies, 1997). The 
extent of tissue damage is the result of the imbalance between the free 
radicals generated and the antioxidant defense system (Machlin and Bendich, 
1987; Stohs, 1995).
11
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Defenses against ROS include enzymes, proteins, and radical 
scavengers. The enzymes superoxide dismutase (SOD), catalase, and 
glutathione peroxidase minimize exposure to ROS by converting O2 * and 
H2O2 to water (Halliwell, 1995). Auxiliary enzymes, including glutathione 
reductase, y-glutamylcysteine synthetase, GSH synthetase, and glucose-6— 
phosphate dehydrogenase, contribute to the antioxidant defense through GSH 
and NADPH biosynthesis or regeneration (Kaplowitz, et.al., 1996). 
Tocopherol, ascorbic acid (reduced), beta-carotene, glutathione, bilirubin, and 
transferrin effectively scavenge ROS and terminate free radical reactions 
(Junod, 1986; Machlin and Bendich., 1987; Kaplowitz, et.al., 1996).
CYPs are an important generator of ROS (Sies, 1997). In addition to 
CYPs, there are several important sources for the generation of ROS.
Electron outflow from mitochondria (Freeman and Crapo, 1982; Richter,
1995), metal accumulation (Kaplowitz and Tsukamoto, 1996), activation of 
nitric oxide synthetase (Bredt and Snyder, 1989), activation of arachidonic 
acid metabolism (Piomelli and Greengard, 1990), and activation of oxidases 
(Simonian and Coyle, 1996) all lead to the production of ROS.
The brain is more susceptible to oxidative damage than other organs. 
Brain tissue is characterized by high oxygen consumption, high content of
12
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polyunsaturated lipids, accumulation of iron in certain brain regions, and 
relatively low catalase activity. All these features make the brain susceptible 
to oxidative injury (Halliwell, 1989). Oxidative stress occurring in 
neurodegenerative disorders shows remarkable cellular selectivity (Simonian 
and Coyle, 1996). Astrocytes maintain relatively high intracellular 
concentration of GSH and recycle ascorbate, which make astrocytes more 
resistant to oxidative damage than neurons and oligodendrocytes (Wilson, 
1997; Peuchen, et.al., 1997). In addition, the neuroprotective effect of 
astrocytes may partially prevent neurons from oxidative damage (Wilson, 
1997).
In contrast to the brain, the liver contains higher levels of the metabolic 
enzymes that generate ROS during mixed-function oxidation. However, the 
liver also has a much stronger antioxidative defense, including higher levels 
of glutathione and glutathione peroxidase (Makar, et.al., 1994).
Glutamate and Glutamate Homeostasis:
Glutamate is the major excitatory neurotransmitter in the central 
nervous system (CNS). Glutamatergic transmission is involved in several 
important brain frmctions, such as learning and memory (Bliss and 
Collingridge, 1993). However, at elevated extracellular concentrations.
13
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glutamate can produce neuronal damage, a phenomenon know as 
excitotoxicity (Choi, 1992). Several neurodegenerative diseases, including 
stroke, epilepsy, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS), 
and Alzheimer’s Disease, are potentially linked to glutamatergic 
excitotoxicity (Gegelashvili and Schousboe, 1997).
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Figure 3. Schematic model for glutamate regulation. NMD A, NMDA receptor; AMPA, 
AMPA receptor; KA, KA receptor; ACPD-G, G-protein coupled-AMPA receptor; PLC, 
phospholipase C. (NichoUs and Attwell, 1990)
Glutamate is distributed throughout the entire central nervous system 
(Monaghan, et.al., 1989). This amino acid neurotransmitter is packaged in 
synaptic vesicles within glutamatergic presynaptic terminals and released into
14
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the synaptic cleft upon stimulation (Nicholls and Attwell, 1990). After 
release, glutamate activates receptors on pre- and postsynaptic neuronal and 
glial membranes. Excitatory transmission and complex signaling processes, 
such as long term potentiation (LTP), long term depression (LTD), and 
neuronal plasticity are evoked through the activation of glutamatergic 
ionotropic and metabotropic receptors (Cotman, et.al., 1989; Collingridge and 
Wolf, 1991). The amount of glutamate in the synaptic cleft is less than 1 pM 
in resting conditions, while the value can transiently reach 10'  ̂M when 
glutamate release is stimulated (Fonnum, 1984; Nicholls and Attwell, 1990). 
The glutamate in extracellular space is rapidly transported into astrocytes and 
presynaptic neurons by glutamate transporters located in neurons and glia. 
This action terminates glutamate synaptic transmission and prevents the 
extracellular glutamate concentration from reaching neurotoxic levels 
(Nicholls and Attwell, 1990). Glutamate is metabolized to glutamine by 
glutamine synthetase (GS) , an astrocytic enzyme, via an ATP dependent 
mechanism. Glutamine is transported from astrocytes back to neurons and 
converted to glutamate by glutaminase in presynaptic neurons (Hamberger, 
et.al., 1979). The synthesis, release, uptake, and metabolism of glutamate 
constitute the glutamine cycle in CNS. Changes in the glutamine cycle, such
15
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as increased release of glutamate, loss of the glutamate transporter, or 
inhibition of glutamine synthetase activity, may disrupt glutamate 
homeostasis in the CNS, leading to elevated extracellular glutamate and 
excitotoxicity (Bristol, and Rothstein, 1996; Trop, et.al., 1995). For example, 
inhibition of GS by methionine sulfoximine triggers convulsant activity 
(Rowe, et.al., 1969).
Growing evidence links oxidative stress and excitotoxic cell death 
(Dykens, et.al, 1987). Both GS and glutamate transporters have been 
reported to be inactivated by ROS in vivo and in vitro (Oliver, et.al., 1990; 
Sorg, 1997). Free radicals can also increase the release of glutamate, leading 
to increased glutamate in the synaptic cleft and prolonged glutamatergic 
signals (Volterra, et.al., 1994). Following the activation of kainic acid (KA) 
and N-methyl-D-aspartate (NMDA) receptors, the increase of intracellular 
Ca^  ̂leads to the activation of nitric oxide synthetase, xanthine oxidase, and 
release of arachidonic acid. These effects greatly increase the generation of 
ROS (Lafon-Cazal, et.al, 1993; Sun, et.al., 1992). Oxidative damage to lipids 
occurs following the activation of glutamate receptors (Puttfarcken, et.al., 
1993). In addition, antioxidants protect neurons against excitotoxic cell death 
(Miyamoto, et.al., 1989)
16
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Loss of GS activity is generally considered as a sensitive indicator of 
tissue oxidative injury (Oliver, et.al., 1990). The activity of GS, a key 
enzyme regulating glutamate homeostasis and ammonia metabolism in the 
CNS, decreases to 65% of control value after 2 hour reperfusion following 10 
minutes ischemia. The reduction of GS activity is effectively prevented by 
preadrnmistration of free radical spin trap reagents (Oliver, et.al., 1990). 
Oxidative inactivation of GS involves the oxidation of His-269, Arg-344, and 
unfolding of the peptide chain, which makes the enzyme susceptible to 
proteases (Roseman and Levine, 1987).
Proposed Research:
Increased GYP lA l activity is associated with elevated generation of 
ROS in 3-MC treated rats (Mishin, et.al., 1975), and induction of GYP lA l by 
TGDD in hepatoma cells has been reported to cause oxidative DNA damage 
(Park, et.al., 1996). All this evidence suggests that induction of GYP lA l 
may increase oxidative stress in vivo. The presence of GYP lA l in the GNS 
is well documented (Warner, et.al., 1991; Kohler, et.al, 1988). Investigation 
of the interaction between GYP induction and oxidative damage in the brain is 
a relatively new research area. Most research has been carried out on GYP 
2E1, the enzyme induced by ethanol. However, the effect of ethanol on
17
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oxidative damage is complicated by increased ROS formation by mitochondria 
(Kukielka, et.al., 1994) as well as metabolism of ethanol by various oxidases 
(Montoliu, et.al., 1995). The regulatory effect of CYP 1A1 induction on 
oxidative status of the brain has not been reported. In the present study, we 
investigated whether induction of CYP 1A1 can cause oxidative damage to 
lipids and proteins, and affect GS activity in the brain and liver. Although 
acute exposure to PAHs and HAHs does not lead to neurotoxicity (Izdebska- 
Szymona, et.al, 1997; Unkila, et.al., 1995), the investigation of their ability to 
cause or exacerbate oxidative damage may help to elucidate their role in other 
CNS pathologies.
18
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Specific Objectives:
The overall goal of this project is to investigate the interaction between 
CYP 1A1 induction and oxidative damage in the brain and liver. We 
hypothesized that induction of CYP 1A1 following exposure to PAHs and 
HAHs causes oxidative damage, and alters GS activity in the brain.
The following questions were addressed in the project:
1. Does 3-MC induce CYP lA l in rat brain and liver? Does the 
dosing regimen affect the extent of CYP 1A1 induction in the brain and liver?
2. Does increased CYP 1A1 activity lead to more protein oxidation and 
lipid peroxidation in rat brain and liver?
3. Does increased CYP lA l activity change the susceptibility of the 
brain and liver to oxidative challenge?
4. Does induction of CYP 1A1 affect GS activity in rat brain and liver?
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Materials and Methods
Materials:
All chemicals were obtained either from Sigma (St. Louis, MO) or 
from Fisher Scientific (Pittsburgh, PA) except 7-ethoxyresorufin (Biomol, 
Plymouth, PA) and protein assay dye reagent (Bio-Rad, Hercules, CA). 
Animal Treatment:
Male Sprague-Dawley rats (150-200 g) were purchased from Simonsen 
Labs (Gilroy, CA). Rats were maintained on a 12 hour light-dark cycle with 
food and water ad libitum. Rats were allowed to adjust from shipping for 4- 
5 days prior to beginning of experiments. 3-MC was suspended in com oil at 
a concentration of 55 jumol/ml. Com oil or 3-MC was administered to rats 
using two different schemes;
1. Five daily intraperitoneal injections of 110 pmol/Kg 3-MC or 2 
ml/kg com oil (Dhawan, et.al, 1990).
2. A single intraperitoneal injection of 550 pmol/Kg 3-MC or 10 ml/Kg 
com oil.
The rats were sacrificed one day, three days, five days, and ten days 
after the last injection, n = 6-12 for each treatment.
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Microsomal Protein Preparation:
The rats were decapitated and the whole rat brain and tissues from the 
biggest lobe of liver were quickly removed and rinsed in homogenization 
buffer (150 mM NaCl, 67 mM Na2HP0 4 , 1 mM EDTA, 0.1 mM PMSF and 
20% glycerol, pH = 7.4). One hemisphere of the brain and half of the liver 
tissue were quickly frozen in a dry ice-ethanol bath and stored at -80 °C. The 
other half of the tissues were used for brain and liver microsomal protein 
preparation.
Rat brain and liver microsomes were prepared as described by Zhang 
(1997). The brain and liver tissues were minced in approximately 15 ml of 
homogenization buffer and homogenized by 10-12 strokes using a 15 ml 
Wheateon Glass/Glass homogenizer and a Teflon pestle. Tissue 
homogenates were centrifuged at 2000 x g for 10 minutes to remove cell 
debris, followed by centrifugation of the supernatants at 10,000 x g for 20 
minutes to remove mitochondria and nuclei. The supernatants were 
centrifuged at 110,000 x g in an ultra-centrifuge for 60 minutes. All 
centrifugations were carried out at 4 °C. The resulting supernatants were 
saved and stored at -80 °C for glutamine synthetase activity assay. The 
pellets were suspended in 800 pi of microsomal suspension buffer (67 mM
21
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N32HP04, 1 mM EDTA, 0.1 mM pepstatin, 0.1 mM leupeptin, 0.1 mM 
PMSF and 20% glycerol, pH = 7.4) and transferred to a 1 ml glass 
homogenizer. After 6-7 strokes for homogenization, the microsomal protein 
suspensions were stored at -80 °C for no more than 30 days before assaying 
for CYP lA l activity.
CYP lA l Activity Assay:
The CYP 1A1 activity in rat brain and liver microsomal proteins were 
quantified by the ethoxyresorufm-O-deethylase (EROD) method as described 
by Unkila with minor changes (Unkila, et.al., 1993). Aliquots (0.2 mg protein 
for brain microsomes and 0.04 mg protein for liver microsomes) of the 
microsomal suspensions in 67 mM sodium phosphate buffer (total volume 1 
ml) were kept on ice. After the addition of 10 pi of 0.5 pM ethoxyresorufin 
ethanol solution, the mixtures were transferred to a semimicro polystyrene 
cuvette and incubated for 10 minutes at 37 °C. The assay was initiated by 
adding 20 pi 50 mM NADPH. The reaction mixtures were incubated at 37 
°C for 15 minutes for brain microsomes and 10 minutes for liver microsomes. 
Resulting fluorescence was measured at 585 nm with excitation at 550 nm 
using an Hitach F2000 fluorescence spectrophotometer. Non-specific
22
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fluorescence for the samples was measured using boiled, denatured samples 
following the same protocol.
The amount of resorufin produced in the tissue homogenate 
suspensions was calculated based on a standard curve developed from a 
range of resorufin concentration in the presence of 5 pM ethoxyresorufin and 
1 mM NADPH. Standards ranged from 0-15 nM for brain microsomes, 0-3 
pM for 3-MC treated rat liver microsomes, and 0-50 nM resorufin for com oil 
treated rat liver microsomes.
To confirm the assay condition, EROD assay was also carried out after 
incubating some brain or liver microsomes at 37 °C with 50 pM a-NF, a 
potent CYP 1A1 inhibitor, for ten minutes.
The time-course relationship for CYP 1A1 activity in rat brain and liver 
was established for both schemes. The 3-MC-treated rats with maximum 
CYP 1A1 activity in the brain or liver and the corresponding com oil-treated 
controls were further used for lipid peroxidation and protein oxidation assays. 
Lipid Peroxidation Assay:
The level of lipid peroxidation in rat brain and liver was quantified by 
the thiobarbituric acid method (Buege, et.al., 1978). Frozen rat brain and 
liver tissues prepared as previously described were thawed at room
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
liver tissues prepared as previously described were thawed at room 
temperature. The tissues were cut into small pieces and rinsed twice with 5 
ml 67 mM sodium phosphate buffer (pH = 7.4). The tissues were 
homogenized for 8-10 stokes in about 5 ml homogenization buffer at 4 '’C. 
Aliquots (1.5 mg protein) of tissue homogenates were mixed with 0.05 M 
Tris-HCl buffer (pH = 7.4) to a final volume of 1.5 ml. The reaction were 
allowed to proceed at 37 °C for 10 minutes. Aliquots (1.5 ml) of TCA-TBA- 
HCl reagent (15% w/v trichloroacetic acid, 0.375% w/v thiobarbituric acid 
and 0.25 M HCl) were then added into test tubes on ice. The reaction 
mixtures were vortexed vigorously and moved to an 80 °C water bath for 15 
minutes. After stopping the reaction on ice, the reaction mixtures were 
centrifuged at 3000 rpm for 5 minutes to remove the flocculent precipitate. 
The absorbance of the supernatant was measured at 535 nm using a Beckman 
DU650 spectrophotometer. Absorbance was corrected by a blank, which 
contained all the reagents except the tissue homogenates.
The amount of thiobarbituric acid-reactive substance (TBARS) in 
tissue homogenates was determined by comparison with a standard curve of a 
range of MDA concentrations from 0-5 nM. MDA standard was prepared by 
hydrolyzing malonaldehyde bis [dimethyl acetal] in 0.05 M Tris-HCl buffer.
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Protein Oxidation Assay:
Protein oxidation in rat brain and liver was quantified by the loss of 
tryptophan fluorescence as described by Davies (Davies and Lin, 1987). 
Aliquots of tissue homogenates (0.7 mg protein) in 67 mM sodium phosphate 
buffer (total volume 1.5 ml) were mixed with 100 pi 20% sodium dodecyl 
sulfate (SDS) and incubated at 37 °C for 30 minutes. Fluorescence for 
tryptophan in the samples was measured at 340 nm with excitation at 280 nm 
using an Hitach F2000 fluorescence spectrophotometer.
The effect of 3-MC treatment on protein oxidation was determined by 
comparing tryptophan fluorescence between com oil-treated and 3-MC- 
treated rats.
Oxidative Challenge:
The brain and liver homogenates (1.5 mg protein), prepared as 
described in the lipid peroxidation assay, were incubated at 37 °C for 10 
minutes. Ten microliters of 15 mM NADPH, 10 pi of 15 mM FeCls, and 50 
pi of 51 mM ADP were added to tissue homogenates and incubated at 37 °C 
for 10 more minutes. The amounts of MDA generated was examined by 
reacting with thiobarbituric acid as described in the lipid peroxidation assay. 
In order to examine the effect of CYP lA l on lipid peroxidation under
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oxidative challenge, a-NF (50 luM) was incubated with tissue homogenates 
for ten minutes before oxidative challenge.
Protein oxidation was also investigated by measuring tryptophan 
fluorescence after oxidative challenge. Brain and liver homogenates (0.7 mg 
protein) in 67 mM sodium phosphate buffer (total volume 1.5 ml) were first 
incubated with 100 pi of 20% sodium dodecyl sulfate (SDS) at 37 °C for 20 
minutes. Then 10 pi of 15 mM NADPH, 10 pi of 15 mM FeCb, and 50 pi of 
51 mM ADP were added to tissue homogenates and incubated at 37 °C for 10 
more minutes. Tryptophan fluorescence was measured as previously 
described.
Glutamine Synthetase Assay:
Glutamine synthetase activity was determined by the method of 
Meister (1985). The supernatants from the 110,000 x g centrifugation in the 
microsomal preparation were used to determine GS activity. Aliquots (0.4 mg 
protein) of the supernatants were added to 750 pi of a solution containing 0.1 
M L-glutamine, 0.125 M hydroxylamine, 0.4 mM manganese chloride, 20 
mM arsenic acid and 0.8 mM ADP. Sufficient volume of 67 mM sodium 
phosphate buffer (pH=7.4) was added to make the final volume 1.5 ml.. The 
reaction was carried out at 37 °C for 60 minutes. The reaction was stopped
26
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
by removing the samples to an ice bath and adding 1.5 ml of 0.37 M ferric 
chloride. After allowing 30 minutes for color development, samples were 
centrifuged at 3000 rpm for 5 minutes to remove any debris. The absorbance 
at 555 nm for the supernatants was read on a Beckman DU 650 
spectrophotometer.
The amount of y-glutamyl hydroxymate (g-GH) produced was 
determined by comparison with a standard curve of a range of g-GH 
concentrations from 0-0.8 pM.
Protein Assay:
The protein content in samples were determined by the Bradford 
method (Bradford, 1976). Samples and protein standards were reacted with 
four-fold diluted protein assay dye reagent for 10 minutes at room 
temperature. The absorbance for the reaction mixtures was measured at 595 
nm by a Beckman DU650 spectrophotometer.
Statistical Analysis:
Statistical analysis was carried out using the GBSTAT ® program. 
Treatment means were compared using ANOVA and the Newman-Keuls test.
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Results:
Identifîcatioi» of CYP lA l Reaction Conditions:
Preliminary studies were performed to optimize the EROD assay 
conditions. Table 1 shows that the highest CYP lA l activity after 10 minutes 
of incubation was observed with 0.2 mg of brain and 0,04 mg of liver 
microsomal protein. Using these established amounts of protein, the reaction 
was allowed to proceed 2-30 minutes. Maximum CYP 1A1 activity occurred 
at 15 minutes in brain microsomes and 10 minutes in liver microsomes (Table 
2). Therefore, 0.2 mg protein and 15 minutes reaction time were used in 
EROD assays for brain microsomes, and 0.04 mg protein and 10 minutes 
reaction time with liver microsomes.
Multiple Injection Protocol:
The induction of CYP lAl in rat brain and liver by 5 daily injections of 
3-MC are shown in Figure 4 and Figure 5. Three days after the last dose, 3- 
MC induced approximately a 7-fold increase in brain CYP lA l activity.
CYP lA l activity was 1.092 ±0.155 pmol resorufin/min/mg protein 
following 3-MC treatment and 0.173 ± 0.06 pmol resorufin/min/mg protein in 
com oil controls. No significant CYP lAl induction occurred one day, five 
days, or ten days after multiple doses of 3-MC in rat brain. In contrast, CYP
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lA l activity was increased in 3-MC treated rat liver one day after the 
treatment. 3-MC treatment increased CYP lA l activity about 60-100 fold at 
all time points. The increased enzyme activity in the brain and liver was 
effectively inhibited by 50 pM a-NF, a selective CYP lA l inhibitor (Table
3).
Figures 6 and 7 show the amount of lipid peroxidation in rat brain and 
liver following 3-MC treatment, and the additional thiobarbituric acid-reactive 
substances (TBARS) generation following oxidative challenge. Three days 
after dosing, the time when maximum CYP lA l activity was observed in both 
brain and liver, 3-MC treatment did not change the amount of lipid 
peroxidation in either tissue. The rate of TBARS generation was 0.27-0.3 
nmol/min/mg protein in the brain and 0.16-0.21 nmol/min/mg protein in the 
liver. 3-MC treatment did not increase lipid peroxidaton over that seen with 
com oil-treated rats. In rat brain, oxidative challenge significantly increased 
the levels of lipid peroxidation in 3-MC and com oil-treated rats. However, 
this increase was not inhibited by 50 pM a-NF in either case. In rat liver, the 
level of lipid peroxidation did not increase following oxidative challenge and 
the addition of 50 pM a-NF did not change the rate of TBARS generation 
after oxidative challenge.
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Figure 8 shows the extent of protein oxidation in rat brain and liver 3 
days after 3-MC and com oil treatment. The loss of tryptophan fluorescence 
in tissue homogenates serves as a marker for protein oxidation. 3-MC did not 
increase brain protein oxidation. 3-MC treatment produced a 7.7% decrease 
in tryptophan fluorescence in rat liver protein. The tryptophan fluorescence is 
115 ± 0.787 in 3-MC-treated rats, which is significantly lower than the 125 ±
2. 62 value of com oil-treated rats.
Figures 9 and 10 show the effect of 3-MC treatment on GS activity in 
the brain and liver. Neither brain nor liver GS activity was changed following 
the induction of CYP lA l by multiple injections of 3-MC. Average GS 
activity was 28-40 nmol/min/mg protein in rat brain, and 6-9 nmol/min/mg 
protein in rat liver in both 3-MC and com oil groups.
Single Dose Protocol:
A single dose of 3-MC did not increase CYP lA l activity in rat brain 
at any measured time point. The brain CYP lA l activity was almost 
unmeasurable in most rats. Conversely, 3-MC caused a marked induction of 
CYP lA l in rat liver. A 55-75 fold increase in CYP lA l activity was 
observed one day, three days, five days, and ten days after treatment (Fig.
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11). CYP lA l activity was relatively close to the corresponding values in the 
multiple injection protocol.
Figure 12 and figure 13 present data showing that a single injection of 
3-MC did not increase lipid peroxidation in rat brain and liver. A single dose 
of 3-MC produced similar levels and a similar pattern of lipid peroxidation as 
that seen with rats receiving multiple doses of 3-MC.
The effect of a single dose of 3-MC on protein oxidation was 
investigated in the brain and liver (Fig. 14). 3-MC exposure did not increase 
protein oxidation in rat brain five days after treatment, while significantly 
decrease liver tryptophan fluorescence to 91.6% of the value seen with com 
oil-treated rats.
Oxidative challenge significantly oxidized brain protein (Fig. 15). The 
tryptophan fluorescence markedly decreased from 166.8 ± 1.84 to 28.3 ±
1.24 following exposure to ADP, iron, and NADPH.
GS activity in rat brain and liver was not altered by 3-MC treatment at 
any time point (Fig. 16, Fig. 17). The values of 23-30 nmol/min/mg protein 
and 6-7 nmol/min/mg protein for the brain and liver GS activity respectively, 
were in the same range as the values from the first treatment protocol.
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Table 1. Effect of Protein Content on CYP lA l Activity:
Microsomes Protein
(mg)
Reaction Time 
(min)
CYP lA l Activity 
(pmol resorufin/min/mg protein)
Brain 0.2 10 1.32 + 0.22
0.4 10 ** 0.83 ±0.16
(nmol resorufin/min/mg protein)
Liver 0.04 10 4.73 ± 0.45
0.08 10 3.87 + 0.38
** = Significantly different from the CYP lA l activity measured at 0.2 mg 
protein (P < 0.05).
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Table 2. Effect of Reaction Time on CYP lA l Activity.
Microsomes Protein Reaction Time CYP lA l Activity
(mg) (min) (pmol resorufin/min/mg protein)
Brain 0.2 2 ** 0
0.2 5 * 0.98 ±0.26
0.2 10 1.13 ±0.30
0.2 15 1.32 ±0.22
0.2 30 * 0.96 ±0.11
(nmol resorufin/min/mg protein)
Liver 0.04 2 ** 2.40 ± 0.34
0.04 5 3.72 ±0.83
0.04 10 4.72 ± 0.46
0.04 15 4.20 ± 0.29
0.04 30 * 3.06 ±0.15
* = CYP lA l activity is significantly different from the highest value (* P < 
0.05, **P<0.01)
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Figure 4. Effect of 5 daily injections of 3-MC on CYP 1A1 activity in 
rat brain. CYP lA l activity in rat brain was determined 1 day, 3 days, 5 
days, and 10 days after 3-MC treatment. CYP lA l activity was expressed as 
pmol resorufin generated/min/mg protein. Each data point represents mean ± 
SEM (n = 6-12). ** = CYP lA l activity significantly increased over
corresponding values from com oil-treated rats (P < 0.01).
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Figure 5, Effect of 5 daily injections of 3-MC on CYPlAl activity in 
rat liver. CYP 1A1 activity in rat liver was determined 1 day, 3 days, 5 days, 
and 10 days after 3-MC treatment. CYP lAl activity was expressed as nmol 
resorufin generated/min/mg protein. Each data point represents mean ± SEM 
(n = 6-12). ** = CYP lA l activity significantly increased over corresponding 
values from com oil-treated rats. # #= CYP lA l activity is significantly 
higher than any other time point (P < 0.01).
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Table 3. Effect of a-NF on CYP lA l Activity.
Microsomes Protein
(mg)
a-NF
(pM)
CYP lA l Activity 
(pmol resorufin/min/mg protein)
Brain 0.2 0 1.09 + 0.15
0.2 50 ** Q
(nmol resorufin/min/mg protein)
Liver 0.04 0 4.70 + 0.32
0.04 50 ** 0.054 ± 0.003
** = The CYP lA l activity is significantly different than that seen without a- 
NF(P<0.01).
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Figure 6. Lipid peroxidation in 3-MC and com oil treated rat brain. 
The amount of lipid peroxidation in 3-MC and com oil treated rats brain was 
evaluated 3 days after multiple injections, and expressed as nmol 
TBARS/min/mg protein. CONT = extent of lipid peroxidation without 
oxidative challenge. OX = lipid peroxidation following oxidative challenge. 
OX + aNF = lipid peroxidation in the brain after treating with oxidative 
challenge and a-NF. Each data point represents mean ± SEM (n=6-7). ** = 
The amount of lipid peroxidation significantly increased over corresponding 
CONT value (P < 0.01).
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Figure 7. Lipid peroxidation in 3-MC and com oil treated rat liver. 
Lipid peroxidation was examined in 3-MC and com oil treated rat liver 3 
days after multiple injections. The amount of lipid peroxidation was shown 
as nmol TBARS/min/mg protein. Assay conditions were the same as in Fig. 6. 
Each data point represents mean ± SEM (n=6-7).
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Figure 8. Protein oxidation in 3-MC and com oil-treated rat brain and 
liver. Protein oxidation was examined in the brain and liver 3 days after 
treatment. The amount of protein oxidation were determined by the loss of 
tryptophan fluorescence at 345 nm. Each data point represents mean ± SEM 
(n=6-7). * = The level of tryptophan fluorescence significantly different from 
com oil group (* P < 0.05).
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Figure 9. GS activity in 3-MC and com oil-treated rat brain. OS 
activity in rat brain was determined 1 day, 3 days, 5 days, and 10 days after 5 
doses of 3-MC or com oil. GS activity is expressed as nmol y-glutamyl 
hydroxymate (g-GH) generated /min/mg protein. Each data point represents 
mean ± SEM (n=6-7).
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Figure 10. GS activity in 3-MC and com oil treated rat liver. GS 
activity in rat liver was determined 1 day, 3 days, 5 days, and 10 days after 5 
doses of 3-MC or com oil. GS activity is expressed as nmol y-glutamyl 
hydroxymate (g-GH) generated/min/mg protein. Each data point represents 
mean ± SEM (n=6-7).
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Figure 11. Effect of a single dose of 3-MC on GYP lAl activity in rat 
liver. GYP lA l activity in rat liver was determined 1 day, 3 days, 5 days, 
and 10 days after the injection. GYP lAl activity was expressed as nmol 
resonifin generated/min/mg protein. Each data point represents mean ± SEM 
(n = 6). ** = GYP lA l activity significantly increased over corresponding 
values from com oil-treated rats (P < 0.01).
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Figure 12. Lipid peroxidation in 3-MC and com oil treated rat brain. 
Lipid peroxidation was evaluated in rat brain 5 days after the single injection. 
The amount of lipid peroxidation was expressed as nmol TBARS/min/mg 
protein. CONT = extent of lipid peroxidation without oxidative challenge. OX 
= lipid peroxidation following oxidative challenge. OX + aNF = lipid 
peroxidation in the brain after treating with oxidative challenge and a-NF. 
Each data point represents mean ± SEM (n=6). ** = The amount of lipid 
peroxidation significantly increased over corresponding CONT value (P < 
0 .01).
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Figure 13. Lipid peroxidation in 3-MC and com oil treated rat liver. 
Lipid peroxidation was examined in rat liver 5 days after the single injection. 
The amount of lipid peroxidation was expressed as nmol TBARS/min/mg 
protein. Assay condition were same as in Fig. 12. Each data point represents 
mean ± SEM (n=6).
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Figure 14. Protein oxidation in 3-MC and com oil treated rat liver. 
Protein oxidation was examined in the brain and liver 5 days after a single 
injection of 3-MC. The amount of protein oxidation were determined by loss 
of tryptophan fluorescence at 345 nm. Each data point represents mean ± 
SEM (n=6). ** = The level of tryptophan fluorescence significantly different 
from com oil (P < 0.01).
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Figure 15. Effect of oxidative challenge on protein oxidation. The 
extent of protein oxidation in rat brain was examined following oxidative 
challenge. Each data point represents mean ± SEM (n=4-6). ** = Protein 
oxidation was significantly increased by oxidative challenge (P < 0.01).
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Figure 16. GS activity in 3-MC and com oil treated rat brain. GS 
activity in rat brain was determined 1 day, 3 days, 5 days, and 10 days after a 
single dose of 3-MC or com oil. GS activity is expressed as nmol y-glutamyl 
hydroxymate (g-GH) generated/min/mg protein. Each data point represents 
mean ± SEM (n=6).
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Figure 17. GS activity in 3-MC and com oil treated rat liver. GS 
activity in rat liver was determined 1 day, 3 days, 5 days, and 10 days after a 
single dose of 3-MC or com oil. GS activity is expressed as nmol y-glutamyl 
hydroxymate (g-GH) generated/min/mg protein. Each data point represents 
mean ± SEM (n=6).
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Discussion
Two well established protocols were used to induce CYP 1A1 in the 
brain and liver. Both protocols exposed rats to a total of 550 pmol/kg of 3- 
MC. Although this dose is much larger than the estimated environmental 
exposure to PAHs and HAHs (nmol/Kg - pmol/Kg) (McFarland and Clarke, 
1989), it is in the same range as the doses that were used in other studies to 
produce significant increases in CYP lAl activity in the rat brain and liver 
(Dhawan, et.al., 1990; Suarez, et.al., 1975).
CYP lA l activity in the brain and liver was examined one day, three 
days, five days, and ten days after 3-MC treatment (see Figs. 4, 5, and 11).
In order to test whether the dosing regimen affected CYP lA l induction and 
the extent of oxidative damage in tissues, 3-MC (550 pmol/Kg) was 
administered to rats either by five daily injections or a single injection. 
Induction of CYP lA l in the brain and liver had different time-course 
relationships after these two injection protocols. A significant increase in 
CYP lA l activity in rat brain was detected three days after five daily 
injections of 3-MC, while brain CYP lA l activity did not increase at all time 
points after a single dose of 3-MC. Three days after 5 daily injections of 3- 
MC, rat brain CYP lA l activity was 1.092 ±0.155 pmol/min/mg protein in
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our study, which is similar to 1.44 ±0.5 pmol/min/mg protein reported by 
Perrin, et.al. (1990). Dramatically increased CYP lA l activity was observed 
in rat liver at all time points after both protocols. The extent of hepatic 
enzyme induction produced by the single injection protocol was less than that 
seen three days after the multiple injection protocol.
The responses of the brain and liver to 3-MC treatment were 
remarkably different. A relatively transient increase in CYP lA l activity in 
the brain was in contrast to much more persistent induction of CYP 1A1 in 
the liver. 3-MC treatment increased CYP 1A1 activity seven fold in the rat 
brain, which is much lower than the 50-100 fold increase of CYP lA l 
activity in the liver. At all time points after both injection protocols, CYP 
lA l activity ranged from 0-0.173 pmol/min/mg protein and 30-45 
pmol/min/mg protein in the control rat brain and liver, respectively. These 
data are slightly lower than 0.45-0.55 pmol/min/mg protein and 60 
pmol/min/mg protein reported by Perrin, et.al. (1990), using a slightly 
different injection protocol (0.5 ml com oil for 3 days).
Neither treatment protocol led to a sustained increase in CYP 1A1 
activity in the brain. One possible explanation for the short duration of CYP 
induction in the brain is that CYP 1A1 can be destroyed during lipid
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peroxidation (Bast and Haenen, 1984), Another possible explanation is that 
the metabolism of 3-MC may be accelerated by increased CYP lA l activity. 
Although we did not observe increased CYP lA l activity in the brain after a 
single dose of 3-MC, it is still possible that the induction of CYP lAl 
occurred at a time that was not chosen in our protocol. Also, when 
comparing the results of the two protocols in the liver, the multiple dose 
regimen induced more CYP lA l activity. Thus it is possible that the single 
dose protocol was not sufficiently rigorous to induce CYP lAl in the brain.
Adthough the brain is particularly vulnerable to lipid peroxidation, 
TEARS generation did not change following increased CYP lA l activity (see 
Fig. 6). Our finding implies that endogenous antioxidant defense can protect 
the brain from ROS attack of the magnitude that can be generated by 
induction of CYP lAl. Another possible reason for the lack of increase in 
lipid peroxidation is that 3-MC treatment may enhance antioxidant defenses 
by changing the levels of antioxidants. For example, 3-MC transcriptionally 
induces glutathione S-transferase (GST) via AhR (Okey, et.al, 1994). 
Increased GST enhances the secretion of 3-MC metabolites, inhibits lipid 
peroxidation by favoring the reduction of lipid hydroperoxides to stable lipid
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aldehydes, and protects against lipid peroxidation by enhancing the secretion 
of cytotoxic aldehyde products (Nordmann, 1994).
Induction of another CYP isoform is linked with oxidative challenges 
in rat brain. Montoliu, et.al. (1994) demonstrated that rats exposed to ethanol 
for 14 days exhibited induction of CYP 2E1, increased ROS formation, and 
depletion of GSH in the brain. The increased formation of ROS after ethanol 
treatment can be partially inhibited in vitro by CYP 2E1 antibody. However, 
chronic alcohol consumption did not enhance the production of TEARS. 
Conversely, later studies by Montoliu, et.al. (1995) demonstrated that 
fourteen day exposure to 25 mM or 50 mM ethanol induced CYP 2E1 and 
increased lipid peroxidation in astrocytes. However, this study did not 
address the role of oxidases other than CYP 2E1 in ethanol metabolism.
In spite of large increases in CYP lA l activity, neither 5 daily 
injections nor a single dose of 3-MC caused measurable lipid peroxidation in 
the rat liver (see Figs. 7, 13). In our studies, the level of TEARS in the com 
oil-treated rat liver is similar to the value 0.02-0.04 nmol/min/mg protein 
detected by Iba (1988) in rat liver three days after receiving three daily 
injections of 0.4 ml of com oil. Our result is consistent with previous studies 
showing that treatment with 150 pmol/Kg 3-MC for two days did not produce
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lipid peroxidation in rat liver (Suarez, et.al., 1975; Junqueira, et.al., 1991). 
Both results suggest that the hepatic antioxidant defense can effectively 
scavenge oxygen radicals generated by increased CYP lAl. Induction of 
glutathione S-transferase (GST) by 3-MC in the liver may also play a role in 
preventing oxidative damage in the liver.
The minor involvement of CYP 1A1 in lipid peroxidation was 
confirmed by assessing its ability to promote lipid peroxidation following 
oxidative challenge (see Figs. 6, 7, 13). The extent of lipid peroxidation was 
examined after challenging the brain and liver homogenates with ferric 
chloride, ADP, and NADPH, an oxidative challenge system shown by 
Svingen to significantly increase CYP-mediated lipid peroxidation in 
microsomes (Svingen, et.al., 1979). In this oxidative challenge system, 
NADPH promotes CYP lA l activity, ferric chloride catalyzes the generation 
of hydroxyl radicals from H2O2 , and facilitates the decomposition of lipid 
hydroperoxides to peroxyl and alkoxyl radicals (Reiter, 1995). ADP 
enhances the electron outflow from mitochondria (Simonian and Coyle, 
1996). In our study, oxidative challenge dramatically increased the extent of 
lipid peroxidation in the brain, while no change was seen in the liver. CYP 
lA l induction by 3-MC did not lead to more lipid peroxidation in either the
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brain or liver. The effect of oxidative challenge on lipid peroxidation could 
not be inhibited by 50 pM a-NF, a potent CYP 1A1 inhibitor. These results 
indicate that induction of CYP lA l following 3-MC treatment did not 
exacerbate lipid peroxidation in the brain and liver under oxidative stress, 
implying that CYP 1A1 induction can not alter the outcome of oxidative 
stress associated with CNS or hepatic diseases.
Protein oxidation was measured by tryptophan fluorescence method of 
Teale (1959). Tryptophan fluorescence accounts for about 95% of the total 
fluorescence at 345 nm induced by excitation at 280 nm (Teale, 1959). 
Neither 3-MC injection protocol increased brain protein oxidation in our 
study (see Figs. 8, 14). Increased CYP lA l activity in the brain following 3- 
MC treatment did not change protein tryptophan fluorescence, suggesting 
that, similar to lipids, the induction of CYP lA l does not produce measurable 
brain protein oxidation.
In rat liver, both 3-MC-injection protocols decreased the protein 
tryptophan fluorescence by 8-9% (see Fig. 8, 14). This small reduction was 
in contrast to an 80 % decrease in tryptophan fluorescence following 
oxidative challenge (see Fig. 15). Thus the 8-9% reduction in tryptophan 
fluorescence dose not represent major oxidation of hepatic protein.
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Additional evidence that CYP lA l induction did not cause significant 
protein oxidation was found by assessing GS activity. The enzyme activity 
was not changed by either injection protocol in the rat brain and liver (see 
Figs. 9, 10, 16, 17). Brain GS activity ranged from 25-40 nmol/min/mg 
protein and liver GS from 6-9 nmol/min/mg protein in 3-MC and com oil- 
treated rats. These values are consistent with data from others studies, e.g., 
22-35 nmol/min/mg protein for brain GS, and 7-22 nmol/min/mg protein for 
liver GS (Wong, et.al., 1980; Wong and Dunn, 1977). GS is very susceptible 
to oxidative damage (Oliver, et.al., 1990) and oxidized GS is prone to 
cleavage by proteases (Lee, et.al, 1988). However, in our study, elevated 
CYP 1A1 activity in rat brain observed three days after multiple doses of 3- 
MC did not affect brain GS. This result is in accordance with the previous 
study by Bondy and Guo (1994). They reported that intraperitoneal injection 
of 4.5 g/Kg ethanol did not change brain GS activity 2 hours and 18 hours 
after treatment. Under the same conditions, ROS formation was increased 
and GS activity was decreased in the liver.
GS is located in astrocytes in CNS, an environment with relatively high 
antioxidant defenses. This may be an explanation for the stable GS activity in 
the brain following 3-MC treatment. Astrocytes accumulate a-tocopherol
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and ascorbate, contain more glutathione, and exhibit higher GST activity than 
neurons (Wilson, 1997). If more ROS are generated by increased CYP 1A1 
activity, the greater antioxidant defense in astrocytes may prevent detectable 
damage. In addition, the amount of ROS generated in astrocytes has not been 
quantified. Although the minor induction of CYP in the brain may lead to 
more ROS formation, we are unable to compare the increased generation of 
ROS from CYP 1 AI with more severe oxidative injury models that decrease 
GS activity by 40 % (Oliver, et.al., 1990).
The rat liver showed extensive CYP lA l induction after 3-MC 
treatment, which may significantly increase the formation of ROS. However, 
neither multiple doses nor a single dose of 3-MC changed hepatic GS activity 
in our study (see Figs. 10, 17). The levels of GSH, GSH-metabolizing 
enzymes, and catalase are higher in the liver than in the brain (Kretzscgnar, 
1996). ROS generated by CYP lA l may be effectively scavenged by these 
antioxidants. Studies by Bondy and Guo (1994) showed that acute ethanol or 
acetaldehyde treatment cause significant depression of GS in the rat liver. 
Possible reasons for the difference seen with CYP 1A1 and CYP 2E1 
induction include the generation of ROS during ethanol or acetaldehyde
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metabolism by various oxidases, as well as increased ROS formation from 
mitochondria (Montoliu, et.al, 1995; Kukielka, et.al., 1994).
The lack of an effect of CYP lA l induction on brain GS activity 
indicates that exposure to 3-MC does not alter this important component in 
glutamate homeostasis. Moreover, the induction of a much higher level of 
CYP 1A1 activity also failed to affect the much lower level of GS activity 
found in liver. Although GS represents only one part of the glutamine cycle, 
the lack of evidence that CYP lA l produces any oxidative damage makes it 
unlikely that CYP 1A1 induction has any significant effect on glutamate 
homeostasis. These observations also make it unlikely that environmental 
exposure to inducers of CYP 1A1 can influence the excitotoxic component of 
neurologic disorders.
In conclusion, this project explored potential links between PAH 
exposure, oxidative damage, and glutamate homeostasis. Our studies 
demonstrated that induction of CYP 1A1 following 3-MC treatment did not 
oxidize either proteins or lipids, or affect GS activity in the rat brain and liver. 
The dosing regimen of 3-MC affected the induction of CYP 1A1 in the brain 
and liver, while no effect on the extent of oxidative damage was seen in either 
tissue. Furthermore, increased CYP lA l activity did not change the extent of
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lipid peroxidation in the brain and liver following oxidative challenge. The 
inability of 3-MC to depress brain GS suggests that induction of CYP 1A1 
does not disrupt glutamate homeostasis through this important component. If 
increased CYP lA l activity in the brain and liver following 3-MC treatment 
leads to increased ROS formation, the increase is insufficient to overwhelm 
the endogenous antioxidant defense system, produce detectable oxidative 
damage, and alter glutamate homeostasis.
58
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Bibliography
Abraham, K., Krowke, R., Neubert, D. (1988) Pharmacokinetics and 
Biological Activity of 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin. Arch. Toxicol. 
62: 359-368
Bast, A., Haenen, G.R.M.M. (1984) Cytochrome P-450 and Glutathione: 
What is the Significance of Their Interrelationship in Lipid Peroxidation? 
TIBS. 510-513
Bliss, T.V., Collingridge, G.L. (1993) A Synaptic Model of Memory: Long- 
Term Potentiation in the Hippocampus. Nature 361; 31-39
Bondy, S.C., Guo, S.X. (1994) Effect of Ethanol Treatment on Indices of 
Cumulative Oxidative Stress. Eur. J. Pharmacol. 270: 349-355
Bradford, M.M. (1976) A Rapid and Sensitive Method for the Quantitation 
of Microgram Quantities of Protein Utilizing the Principle of Protein-dye 
Binding. Anal. Biochem. 72: 248-254
Bredt, D.S., Snyder, S.H. (1989) Nitric Oxide Mediates Glutamate-linked 
Enhancement of cGMP Levels in the Cerebellum. Proc. Natl. Acad. Sci.
USA 86: 9030-9033
Bristol, L.A., Rothstein, J.D. (1996) Glutamate Transporter Gene Expression 
in Amyotrophic Lateral Sclerosis Motor Cortex. Ann. Neurol. 39: 676-679
Buege, J.A., Aust, S.D. (1978) Microsomal Lipid Peroxidation. Methods. 
Enzymol. 52: 302-310
Brouwer, A., Ahlborg, U.G., Van den Berg, M., Bimbaum, L.S., Boersma, 
E.R., Bosveld, B., Denison, M.S., Gray, L.E., Hagmar, L., Holene, E. (1995) 
Functional Aspects of Developmental Toxicity of Polyhalogenated Aromatic 
Hydrocarbons in Experimental Animals and Human Infants. Eur. J. 
Pharmacol. 293 (1): 1-40
Buege, J.A., Aust, S.D. (1978) Microsomal Lipid Peroxidation. Methods in 
Enzymology. 52: 302-310
59
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Capen, C.C. (1995) Toxic Responses of the Endocrine System, in Casarett 
& DoulTs Toxicology: the Basic of Poisons, eds. Klaassen, C.D. (McGraw- 
Hill) 617-640
Choi, D.W. (1992) Excitotoxic Cell Death. J. Neurobiol. 23:1261-1276
Collingridge, G.L., Wolf, S. (1991) Excitatory Amino Acid Receptors and 
Synaptic Plasticity. Trends Pharm. Sci. 11(12): 508-515
Costa, L.G. (1998) Signal Transduction in Environmental Neurotoxicity. 
Annu. Rev. Pharmacol. Toxicol. 38: 21-43
Cotman, C.W., Bridges, R.J., Taube, J.S., Clark, A.S., Geddes, J.W., 
Monaghan, D.T. (1989) The Role of the NMDA Receptor in Central 
Nervous System Plasticity and Pathology. J. NIK Res. 1 (July/August): 
65-73
Davies, K.J., Lin, S.W. (1987) Protein Damage and Degradation by Oxygen 
Radicals. II. Modification of Amino Acids. J. Bio. Chem. 262 (20): 9902- 
9907
Dhawan, A., Parmar, D., Das, M., Seth, P.K. (1990) Cytochrome P-450 
Dependent Monooxygenases in Neuronal and Glial Cells: Inducibility and 
Specificity. Biochem. Biophys. Res. Comm. 170: 441-447
Dogra, S.C., Whitelaw, M L., May, B.K. (1998) Transcriptional Activation 
of Cytochrome P450 Genes by Different Classes of Chemical Inducers. Clin, 
and Exp. Pharmacol, and Physiol. 25: 1-9
Dykens, J.A., Stem, A., Trenkner, E. (1987) Mechanisms of Kainate 
Toxicity to Cerebellar Neurons in Vitro is Analogous to Reperfusion Tissue 
Injury. J. Neurochem. 49: 1222-1228
Fonnum, F. (1984) Glutamate: a Neurotransmitter in Mammalian Brain. J. 
Neurochem. 42: 1-11
Freeman, B.A., Crapo, J.D. (1982) Free Radical and Tissue Injury. Lab. 
Invest. 47: 412-426
60
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Funae, Y., Imaoka, S. (1991) Cytochrome in Rodents. Handbook of 
Experimental Pharmacology 105:221-238
Gegelashvili, G., Schousboe, A. (1997) High Affinity Glutamate 
Transporters: Regulation of Expression and Activity. Mol. Pharmacol.
52: 6-15
Gonzalez, F.J. (1991) Cytochrome P450 in Humans. Handbook of 
Experimental Pharmacology 105: 239-257
Gonzalez, F.J. (1991) Cytochrome P450 Evolution and Nomenclature. 
Handbook of Experimental Pharmacology 105: 211-219
Guengerich, F.P. (1991) Metabolic Reaction: Types of Reactions of 
Cytochrome P450 Enzymes. Handbook of Experimental Pharmacology 105: 
89-103
Halliwell, B (1989) Oxidants and the Central Nervous System: Some 
Fundamental Questions. Is Oxidant Damage Relevant to Parkinson’s Disease, 
Alzheimer’s Disease, Traumatic Injury or Stroke? Acta. Neurol. Scand. 
Suppl. 126:23-33
Halliwell, B., Aruoma, O.I. (1991) DNA Damage by Oxygen-derived 
Species: Its Mechanism and Measurement in Mammalian Systems. FEBS 
Letters 281: 9-19
Halliwell, B. (1995) Antioxidant Characterization: Methodology and 
Mechanism. Biochem. Pharmacol. 49: 1341-1348
Hamberger, A C., Chiang, G.H., Nylen, E.S., Scheff, S.W., Cotman, C.W. 
(1979) Glutamate as a CNS Transmitter. I. Evaluation of Glucose and 
Glutamine as Precursors for the Synthesis of Preferentially Released 
Glutamate. Brain Res. 168: 513-530
Hankinson, O. (1995) The Aryl Hydrocarbon Receptor Complex. Annu. 
Rev. Pharmacol. Toxicol. 35: 307-340
61
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Higuchi, H., Kurose, I., Kato, S., Miura, S., Ishii. H. (1996) Ethanol-Induced 
Apoptosis and Oxidative Stress in Hepatocytes. Alcohol. Clin. Exp. Res. 
20(9 Suppl): 340A-346A
Hopwell, J.W., Wright, E.A. (1969) The Importance of Implantation Site in 
Cerebral Carcinogenesis in Rats. Cancer Res. 29: 1927-1931
Iba, M.M., Lang, B. (1988) Stimulation of the Conjugation of Lipid Dienes 
in Hepatic Microsomes by 3, 3 '-dichlorobenzidine. Biochem. Pharmacol. 
37(5): 781-791
Izdebska-Szymona, K., Kopec-Szlezak, J., Kozlowska, E., Drela, N., 
Panczyk, S. (1997) Organ Cytotoxicity of Selected Polycyclic Aromatic 
Hydrocarbons in Mice. Rocz. Panstw. Zakl. Hig. 48 (1): 13-21
Jenner, P., Olanow, C.W. (1996) Oxidative Stress and Pathogenesis of 
Parkinson’s Disease. Neurology 47 (6 Suppl 3): S161-S170
Juchau, M.R., DiGiovanni, J., Namkung, M., Jones, A. H. (1979) A 
Comparison of the Capacity of Fetal and Adult Liver, Lung, and Brain to 
Convert Polycyclic Aromatic Hydrocarbons to Mutagenic and Cytotoxic 
Metabolites in Mice and Rats. Toxicol. Appl. Pharmac. 49: 171-178
Junod, A.F. (1986) Data on Oxidants and Antioxidants. Bull. Eur. 
Physiopathol. Respir. 22(1): 253S-255S
Junqueira, V.B., Simizu, K., Pimentel R., Azzalis, L.A., Barros, S B., Koch, 
O., Videla, L. A. (1991) effect of Phénobarbital and 3-Methylcholanthrene 
on the Early Oxidative Stress Component Induced by Lindane in Rat Liver. 
Xenobiotica. 21(8): 1053-1065
Kaplowitz, N., Tsukamoto, H. (1996) Oxidative Stress and Liver Disease. 
Prog. Liver Dis. 14: 131-159
Kappus, H. (1991) Metabolic Reaction: Roles of Cytochrome P450 in the 
Formation of Reactive Oxygen Species. Handbook of Experimental 
Pharmacology 105: 145-154
62
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Kocoba, R.J., Schwetz, B.A. (1982) Toxicity of 2, 3, 7, 8-Tetrachloro 
dibenzo-p-dioxin (TCDD). Drug Metabolism Reviews 13:387-406
Kohler, C., Eriksson, L.G., Hansson, T., Warner, M., Ake-Gustafsson, J. 
(1988) Immunohistochemical Localization of Cytochrome P-450 in the Rat 
Brain. Neuroscience Letters 84: 109-114
Kretzschmar, M. (1996) Regulation of Hepatic Glutathione Metabolism and 
Its Role in Hepatotoxicity. Exp. Toxic. Pathol. 48: 439-446
Krowke, R. (1986) Studies on Distribution and Embryotoxicity of Different 
PCDDs and PCDFs in Mice and Marmosets. Chemosphere 15: 2011-2022
Kukielka, E., Dreker, E., Cederbaum, A.L. (1994) Increased Production of 
Reactive Oxygen Species by Rat Liver Mitochondria after Chronic Ethanol 
Treatment. Arch. Biochem. Biophys. 309: 377-386
Lafon-Cazal, M., Pletri, S., Culcasi, M., Bockaert, J. (1993) NMDA- 
dependent Superoxide Production and Neurotoxicity. Nature 364: 535-537
Landers, J.P., Bunce, N.J. (1991) The Ah Receptor and the Mechanism of 
Dioxin Toxicity. Biochem. J. 276: 273-287
Lee, Y.S., Park, S.C., Goldberg, A.L., Chung, C.H. (1988) Protease So from 
Escherichia Coli Preferentially Degrades Oxidatively Damaged Glutamine 
Synthetase. J. Bio. Chem. 263 (14): 6643-6646
Lieber, C.S. (1997) Role of Oxidative Stress and Antioxidant Therapy in 
Alcoholic and Nonalcoholic Liver Diseases. Adv. Pharmacol 38: 601-628
Liu, D. (1996) The Role of Free Radicals in Amyotrophic Lateral Sclerosis. 
J. Mol. Neurosci. 7 (3): 159-167
Machlin, L.J., Bendich, A. (1987) Free Radical Tissue Damage; Protective 
Role of Antioxidant Nutrients. FEAEB J. 1(6): 441-445
Makar, T.K., Nedergaard, M., Preuss, A., Gelbard, A.S., Perumal, A.S., 
Cooper, A.J.L. (1994) Vitamin E, Ascorbate, Glutathione, Glutathione 
Disulfide, and Enzymes of Glutathione Metabolism in Culture of Chick
63
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Astrocytes and Neurons: Evidence that Astrocytes Play an Important Role in 
Antioxidative Process in the Brain. J. Neurochem. 62: 45-53
Maltony, C., Ciliberti, A., Caretti D. (1982) Experimental Contributions in 
Identifying Brain Potential Carcinogens in the Petrochemical Industry. Ann. 
N. Y. Acad. Sci. 381:216-249
Markesbery, W.R. (1997) Oxidative Stress Hypothesis in Alzheimer’s 
Disease. Free Radie. Biol. Med. 23 (1): 134-147
McFarland, V.A., Clarke, J.U. (1989) Environmental Occurrence, 
Abundance, and Potential Toxicity of Polychlorinated Biphenyl Congeners: 
Considerations for a Congener-Specific Analysis. Environmental Health 
Perspectives. 81: 225-239
Meister, A. (1985) Glutamine Synthetase from Mammalian Tissues. 
Methods. Enzymol. 113: 185-199
Mishin, V.M., Pokrovskii, A.G., Pospelova, L.N., Liakovich, V.V. (1975) 
Interrelation of Oxygen Anion-Radical Generation and Lipid Peroxidation in 
Liver Microsomes. Biull. Eksp. Bio. Med. 80 (12): 28-31
Miyamoto, M., Murphy, T.H., Schnaar, R.L., Coyle, J.T. (1989) 
Antioxidants Protect against Glutamate-induced Cytotoxicity in a Neuronal 
Cell line. J. Pharmacol. Exp. Ther. 250: 1132-1140
Monagan, D.T., Bridges, R.J., Cotman, C.W. (1989) The Excitatory Amino 
Acid Receptors: Their Classes, Pharmacology, and Distinct Properties in the 
Function of the Central Nervous System. Annu. Rev. Pharmacol. Toxicol. 
29: 365-402
Montoliu, C., Valles, S., Renau-Piqueras, J., Guerri, C. (1994) Ethanol- 
Induced Oxygen Radical Formation and Lipid Peroxidation in Rat Brain: 
Effect of Chronic Alcohol Consumption. J. Neurochem. 63: 1855-1862
Montoliu, C., Sancho-Tello, M., Azorin, I., Burgal, M., Valles, S., Renau- 
Piqueras, J., Guerri, C. (1995) Ethanol Increase Cytochrome P450 2E1 and 
Induces Oxidative Stress in Astrocytes. J. Neurochem. 65: 2561-2570
64
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Nicholls, D., Attwell, D. (1990) The Release and Uptake of Excitatory 
Amino Acids. Trends Pharmacol. Sci. 11:462-468
Nobert, D.W., Gonzalez, F.J. (1987) P450 genes: Structure, Evolution, and 
Regulation. Annu. Rev. Biochem. 56: 945-993
Nordmann, R. (1994) Alcohol and Antioxidant Systems. Alcohol. Alcohol. 
29 (5); 513-522
Okey, A.B., Riddick, D.S., Harper, P.A. (1994) The Ah Receptor: Mediator 
of the Toxicity of 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) and 
Related Compounds. Toxicol. Letters 70:1-22
Oliver, C.N., Starke-Reed, P.E., Stadtman, E.R., Liu, G.J., Carney, J.M., 
Floyd, R.A. (1990) Oxidative Damage to Brain Proteins, Loss of Glutamine 
Synthetase Activity, and Production of Free Radicals during 
Ischemia/Reperfusion-induced Injury to Gerbil Brain. Proc. Natl. Acad. Sci. 
USA 87: 5144-5147
Park, J.K., Schigenaga, M.K., Ames, B.N. (1996) Induction of Cytochrome 
P450 lA l by 2, 3, 7, 8-Tetrachlorodibenzo-P-dioxin or Indolo (3, 2-b) 
Carbazole is Associated with Oxidative DNA Damage. Proc. Natl. Acad.
Sci. USA 93: 2322-2327
Parkinson, A. (1995) Biotransformation of Xenobiotics. in Casarett & 
DoulFs Toxicology: the Basic of Poisons, eds. Klaassen, C D. (McGraw-Hill) 
113-187
Perrin, R., Minn, A., Ghersi-egea, J., Grassiot, M., Siest, G. (1990) 
Distribution of Cytochrome P-450 Activities towards Alkoxyresorufin 
Derivatives in Rat Brain Regions, Subcellular Fractions and Isolated Cerebral 
Microvessels. Biochem. Pharmacol. 40 (9): 2145-2151
Peuchen, S., Bolanos, J.P., Heales, S.J., Almeida, A., Duchen, M.R., Clark, 
J.B. (1997) Interrelationships Between Astrocytes Function, Oxidative Stress 
and Antioxidant Status within the Central Nervous System. Prog. Neurobiol. 
52 (4): 261-281
65
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Piomelli, D., Greengard P. (1990) Lipoxygenase Metabolites of Arachidionic 
Acid in Neuronal Transmembrane Signaling. Trends Pharmacol. Sci. 11: 
367-371
Pilot HI, H.C., Yvonne, P.D. (1995) Chemical Carcinogenesis, in Casarett 
& Doull’s Toxicology: the Basic of Poisons, eds. Klaassen, C.D. (McGraw- 
Hill) 201-267
Poellinger L. (1995) Mechanism of Signal Transduction by the Basic Helix- 
loop-helix Dioxin Receptor, in: Baeuerle, P.A. (ed.) Inducible Gene 
Expression, Vol. 1., Birkhauser, Boston. 177-205
Poiger, H., Schlatter, C. (1986) Pharmacokinetics of 2, 3, 7, 8-TCDD in 
Man. Chemosphere 15: 1489-1494
Powis, G. (1989) Free Radical Formation by Antitumor Quinones Free 
Radical. Biol. Med. 6: 63-101
Puttfarcken, P.S., Getz, R.L., Coyle, J.T. (1993) Kainic Acid-induced Lipid 
Peroxidation: Protection with Butylated Hydroxytoluene and U78517F in 
Primary Cultures of Cerebellar Granule Cells. Brain Res. 624: 223-232
Quattrochi, L.C., Tukey, R.H. (1989) The Human Cytochrome CYP 1A2 
Gene Contains Regulatory Elements Responsive to 3-Methylcholanthrene. 
Mol. Pharmacol. 36: 66-71
Ramos, K.S., Chacon, E., Acosta, D.,Jr. (1995) Toxic Responses of the 
Heart and Vascular Systems. Casarett & DoulFs Toxicology: the Basic 
Science of Poisons. Fifth Edition, Ed. Klaassen, C.D. 487-529
Reiter, R.J. (1995) Oxidative Process and Antioxidative Defense 
Mechanisms in the Aging Brain. FASEB J. 9: 526-533
Richter, C., Gogvadze, V., Laffranchi, R., Schlapbach, R., Schweizer, M., 
Suter, M., Walter, P., Yaftee, M. (1995) Oxidants in Mitochondria: from 
Physiology to Diseases. Biochim. Biophys. Acta. 1271(1): 67-74
66
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Rose, J.Q., Ramsey, J.C., Wentzler, T.H., Hummel, R.A., Gehringm P.J. 
(1976) The Fate of 2, 3, 7, 8-Tetrachlorodibenzo-p>dioxin Following Single 
and Repeated Oral Doses to the Rat. Toxicol. Appl. Pharmacol. 36: 209-226
Roseman, I.E., Levine, R,L.(1987) Purification of a Protease from 
Escherichia Coli with Specificity for Oxidized Glutamine Synthetase. J. Biol. 
Chem. 262: 2101-2110
Rouet, P., Alexandrov, K., Markovits, P., Frayssinet, C., Dansette, P.M 
(1981) Metabolism of Benzo[a]pyrene by Brain Microsomes of Fetal and 
Adult Rats and Mice. Induction by 5, 6Benzoflavone, Comparison with Liver 
and Lung Microsomal Activities. Carcinogenesis 2:919-926
Rowe, W.B., Ronzio, R.A., Meister, A. (1969) Inhibition of Glutamine 
Synthetase by Methionine Sulfoximine. Studies on Methionine Sulfoximine 
Phosphate. Biochemistry. 8(6): 2674-2680
Schilter, B., Omiecinski, C. (1994) Regional Distribution and Expression 
Modulation of Cytochrome P-450 and Epoxide Hydroxylase mRNA in the 
Rat Brain. Mol. Pharmacol. 44: 990-996
Sies, H. (1997) Oxidative Stress: Oxidants and Antioxidants. Exp. Physiol. 
82(2): 291-295
Simonian, N.A., Coyle, J.T. (1996) Oxidative Stress in Neurodegenerative 
Diseases. Annu. Rec. Pharmacol. Toxicol. 36: 83-106
Sorg, O., Horn, T.F.W., Yu, N., Gruol, D.L., Bloom, F.E. (1997) Inhibition 
of Astrocytes Glutamate Uptake by Reactive Oxygen Species: Role of 
Antioxidant Enzymes. Mol. Med. 3 (7): 431-440
Srivastava, S. P., Seth, P.K. (1983) 7-Ethoxycoumarin O-Deethylase Activity 
in Rat Brain Microsomes. Biochem. Pharmacol. 32: 3657-3660
Stadtmann, E.R., Starke-Reed, P.E., Oliver, C.N., Carney, J.M., Floyd, R.A.
(1992) Protein Modification in Aging. EXS 62:64-72
Stohs, S.J. (1995) The Role of Free Radicals in Toxicity and Disease. J. 
Basic Clin. Physiol. Pharmacol. 6(3-4): 205-228
67
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Suarez, K.A., Carlson, G.P., Fuller, G.C. (1975) Effect of Phénobarbital or 
3-Methylcholanthrene Pretreatment on Carbon Tetrachloride-Induced Lipid 
Peroxidation in Rat Liver. Toxicol, and Appl. Pharmacol. 34: 314-319
Sun, A.Y., Cheng, Y., Bu, Q., Oldfield, F. (1992) The Biochemical 
Mechanisms of the Excitotoxicity of Kainic Acid. Mol. Chem. Neuropathol. 
17: 51-63
Svingen, B.A., Buege, J.A., O’Neal, F.O., Aust, S.D. (1979) The Mechanism 
of NADPH-dependent Lipid Peroxidation. The Propagation of Lipid 
Peroxidation. J. Bio. Chem. 254: 5982-5989
Teale, F.W.J. (1959) The Ultraviolet Fluorescence of Proteins in Neutral 
Solution. Bioch. 76: 381-388
Tomas, J.A. (1995) Toxic Responses of the Reproductive System, in 
Casarett & DoulFs Toxicology: the Basic of Poisons, eds. Klaassen, C.D.. 
(McGraw-Hill) 547-581
Torp, R., Lekieffre, D., Levy, L.M., Haug, F.M., Danbolt, N.C., Meldrum, 
B.S., Ottersen, O.P. (1995) Reduced Postischemic Expression of a Glial 
Glutamate Transporter, GLTl, in the Rat Hippocampus. Exp. Brain Res.
103: 51-58
Unkila, M., Pohjanvirta, R., Honkakoski, P., Torronen,R., Tuomisto, J.
(1993) 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) Induced 
Ethoxyresorufin-O-deethylase (EROD) and Aldehyde Dehydrogenase 
(ALDH3) Activities in the Brain and Liver. A Comparison Between the Most 
TCDD-susceptible and the Most TCDD-resistant Rat Strain. Biochem. 
Pharmacol. 46 (4): 651-659
Unkila, M., Pohjanvirta, R., Tuomisto, J. (1995) Biochemical Effects of 2, 3, 
7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) and Related Compounds on the 
Central Nervous System. Int. J. Biochem. Cell Biol. 27 (5): 443-455
Volterra, A., Trotti, C., Tromba, C., Floridi, S., Racagni, G. (1994)
Glutamate Uptake Inhibition by Oxygen Free Radicals in Rat Brain Cortical 
Astrocytes. J. Neurochem. 14: 2924-2932
68
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Warner, M., Kohler, C., Hansson, T., Gustafsson, J-A. (1988) Regional 
Distribution of Cytochrome P450 in the Rat Brain; Spectral Quantitation and 
Contribution of P450 b,e and c, d. J. Neurochem. 50: 1057-1065
Warner, M., Gustafsson, J-A. (1991) Extrahepatic Microsomal Forms: Brain 
Cytochrome P450. Handbook of Experimental Pharmacology. 105:387-397
Wilson, J.X. (1997) Antioxidant Defense of the Brain: A Role for 
Astrocytes. Can. J. Physiol. Pharmacol. 75 (10-11): 1149-1163
Wolff, M.S., Collman, G.W., Barrett, J.C., Huff, J. (1996) Breast Cancer and 
Environmental Risk Factors: Epidemiological and Experimental Findings. 
Annu. Rev. Pharmacol. Toxicol. 36: 573-596
Wong, B.S., Dunn, A. (1977) Possible Growth Hormone Regulation of Rat 
Liver Glutamine Synthetase Activity. Biochem. Biophys. Res. Commun. 
79(3): 876-884
Wong, B.S., Chenoweth, M.E., Dunn, A (1980) Possible Growth Hormone 
Control of Liver Glutamine Synthetase Activity in Rats. Endocrinology 
106(1): 268-274
Zhang, Q.Y., Kaminsky, L. (1997) Induction of CYP lA l by Beta- 
naphthoflavone in IEC-18 Rat Intestinal Epithelial Cells and Potentiation of 
Induction by Dibutyryl cAMP. Biochem. Biophys. Res. Commun. 233 
(3):623-626
69
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
